Table 2.
Fracture and Cardiovascular Event Rates in Aromatase Inhibitor Versus Tamoxifen Studies
| Study | Drug | N | Duration (months) | Fractures | Cardiovascular events | ||
|---|---|---|---|---|---|---|---|
| % | (N) | % | (N) | ||||
| ATAC64 | Anastrozole | 3125 | 100 | 16.6 | (521)* | 1.9 | (60) |
| Tamoxifen | 3116 | 12.0 | (377) | 1.9 | (61) | ||
| BIG 1–9843 | Letrozole | 2448 | 40 | 8.0 | (196)* | 5.7 | (140) |
| Tamoxifen | 2447 | 5.4 | (132) | 5.2 | (127) | ||
| IES65 | Exemestane | 2320 | 55 | 4.3 | (100)* | 16.4 | (382) |
| Tamoxifen | 2338 | 3.1 | (73) | 15.0 | (350) | ||
* P< 0.05.
Arimidex, Tamoxifen Alone or in Combination trial, Breast International Group 1-98 trial, Intergroup Exemestane Study.